soventec is lead partner in EMECK - Development of an AI software solution for early cancer detection

Heading Text

soventec GmbH, the University of Lübeck and UKSH an are starting a joint research project to develop a novel sofware system for early cancer detection specifically for pancreatic, colon and lung cancer. This system will for the first time be able to evaluate multiple biomarkers in combination clinical patient data with an AI-based evaluation strategy to perform a differentiated and unambiguous early cancer detection.

The project combines the expertise of the University of Lübeck in the areas of biobanking and sensitive biomarker detection and soventec in the development of the software and AI-based evaluation modules.

"Pancreatic, colorectal and lung cancers are among the most common cancers worldwide and the majority have tumor involvement in lymph nodes and/or distant organs at the time of diagnosis. A major challenge for today's healthcare systems worldwide is the difficulty in detecting cancer patients at an early stage without metastasis with greater chances of cure," explains Prof. Dr. Timo Gemoll, Acting Section Head of the Section for Translational Surgical Oncology & Biomaterial Banks (STCOB) of the Department of Surgery at the University Hospital Schleswig-Holstein, Lübeck Campus and the University of Lübeck. Furthermore, it would be desirable to predict a therapy response for affected patients, e.g. to make statements about the success of chemotherapy or radiation.

Automated early cancer detection with the use of AI

"What is new, is that we will try combinate raw measurement from laborytory devices with clinical data and patient histories via an AI-based evaluation approach," says Kai Diercks, Managing Director of soventec, describing his company's contribution to the project.

The soventec part of the funding is also supported proportionally from ERDF funds with 193,292.-Euro.

The project partners